Long-term scopolamine treatment and dental caries
- 160 Downloads
To investigate whether scopolamine, an anticholinergic agent which induces hyposalivation, represents a risk factor for the occurrence of dental caries.
Materials and methods
A retrospective cohort study was carried out among sailors treated with scopolamine for seasickness. The study population included 370 young healthy male adults (18–30 years old) who served in the Israel Navy between 2012 and 2016. Of these, 66 subjects who were chronically treated with intermittent administration of scopolamine, either by the oral or transdermal route, were assigned to the study group. Documented subject characteristics included age, socioeconomic status, level of education, body mass index, smoking history, and dental hygiene. Follow-up lasted 1 to 3.5 years.
Two- to 3.5-year follow-up revealed a higher risk of dental caries in 15 of 16 subjects (93.8%) treated with an average of 50.9 mg scopolamine, in contrast to only 71 of 108 control subjects (65.7%) (RR = 1.43, p = 0.02 [95% CI = 1.18–1.72]). Follow-up for 1–1.5 years revealed a lower occurrence of dental caries in both the study group (11/22, 50.0%) and the control group (46/104, 44.2%). Follow-up of 1.5–2 years also revealed less dental caries, in 16/28 subjects (57.1%) in the study group and 51/92 subjects (55.4%) in the control group. The differences were not statistically significant.
In healthy young adults, prolonged intermittent use of scopolamine was found to be a risk factor for the development of dental caries.
Dental care and hygiene should be intensified when administering hyposalivatory anticholinergic agents.
KeywordsDental caries Hyoscine Scopolamine Xerostomia
We are grateful to Richard Lincoln of the Israel Naval Medical Institute for help in editing the manuscript. We thank the enlisted paramedics of the Israel Defense Forces 3rd Flotilla and the staff of the Naval Dental Clinic for gathering some of the data.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
Ethical approval for this study was obtained from the IDF Institutional Review Board.
- 1.Brown JH, Laiken N (2011) Muscarinic receptor agonists and antagonists. In: Brunton LL, Chabner BA, Knollmann BC (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 12th edn. McGraw-Hill, New York, pp 219–237Google Scholar
- 5.American Society of Health-System Pharmacists (2008) AHFS drug information 2008. Bethesda, MDGoogle Scholar
- 11.Fedorova T, Knudsen CS, Mouridsen K, Nexo E, Borghammer P Salivary acetylcholinesterase activity is increased in Parkinson’s disease: a potential marker of parasympathetic dysfunction. Parkinsons Dis 2015, 2015:156479–156477. https://doi.org/10.1155/2015/156479
- 15.Zero DT, Brennan MT, Daniels TE, Papas A, Stewart C, Pinto A, Al-Hashimi I, Navazesh M, Rhodus N, Sciubba J, Singh M, Wu AJ, Frantsve-Hawley J, Tracy S, Fox PC, Ford TL, Cohen S, Vivino FB, Hammitt KM, Sjögren’s Syndrome Foundation Clinical Practice Guidelines Committee (2016) Clinical practice guidelines for oral management of Sjögren disease: dental caries prevention. J Am Dent Assoc 147:295–305CrossRefPubMedGoogle Scholar
- 18.Central Bureau of Statistics (2016) Characterization and classification of local authorities by the socio-economic level of the population 2013. Central Bureau of Statistics, IsraelGoogle Scholar